ARVN Arvinas Inc

Price (delayed)

$32.68

Market cap

$2.24B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.05

Enterprise value

$2.15B

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
The debt has declined by 48% year-on-year and by 19% since the previous quarter
The quick ratio is up by 22% year-on-year
The company's equity rose by 19% YoY but it fell by 8% QoQ
The company's net income fell by 18% YoY but it rose by 3.4% QoQ
The gross profit has contracted by 48% YoY and by 9% from the previous quarter
Arvinas's revenue has decreased by 48% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of ARVN
Market
Shares outstanding
68.43M
Market cap
$2.24B
Enterprise value
$2.15B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.65
Price to sales (P/S)
32.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.09
Earnings
Revenue
$71.3M
EBIT
-$353.4M
EBITDA
-$346.7M
Free cash flow
-$356M
Per share
EPS
-$6.05
Free cash flow per share
-$4.97
Book value per share
$8.96
Revenue per share
$0.99
TBVPS
$16.91
Balance sheet
Total assets
$1.21B
Total liabilities
$602.9M
Debt
$2.6M
Equity
$609.7M
Working capital
$949.5M
Liquidity
Debt to equity
0
Current ratio
4.94
Quick ratio
4.91
Net debt/EBITDA
0.26
Margins
EBITDA margin
-486.3%
Gross margin
100%
Net margin
-497.6%
Operating margin
-556.9%
Efficiency
Return on assets
-30.5%
Return on equity
-64.8%
Return on invested capital
-48.3%
Return on capital employed
-36.4%
Return on sales
-495.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
1.78%
1 week
3.94%
1 month
-2.3%
1 year
40.86%
YTD
-20.6%
QTD
-20.83%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$71.3M
Gross profit
$71.3M
Operating income
-$397.1M
Net income
-$354.8M
Gross margin
100%
Net margin
-497.6%
Arvinas's operating margin has plunged by 161% YoY and by 9% from the previous quarter
The net margin has dropped by 127% year-on-year and by 6% since the previous quarter
The gross profit has contracted by 48% YoY and by 9% from the previous quarter
Arvinas's revenue has decreased by 48% YoY and by 9% from the previous quarter

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
N/A
P/B
3.65
P/S
32.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.09
The EPS has grown by 9% from the previous quarter but it has contracted by 7% YoY
The stock's price to book (P/B) is 24% less than its 5-year quarterly average of 4.8 but 11% more than its last 4 quarters average of 3.3
The company's equity rose by 19% YoY but it fell by 8% QoQ
The P/S is 54% above the last 4 quarters average of 21.4 but 36% below the 5-year quarterly average of 51.6
Arvinas's revenue has decreased by 48% YoY and by 9% from the previous quarter

Efficiency

How efficient is Arvinas business performance
The ROS has plunged by 139% YoY and by 6% from the previous quarter
The company's return on invested capital has shrunk by 56% YoY but it rose by 7% QoQ
ARVN's return on assets is down by 31% year-on-year but it is up by 4.1% since the previous quarter
ARVN's return on equity is down by 28% year-on-year but it is up by 8% since the previous quarter

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
ARVN's total assets is 101% more than its total liabilities
ARVN's current ratio is up by 22% YoY
The quick ratio is up by 22% year-on-year
The debt is 100% smaller than the equity
The debt to equity has plunged by 100% YoY
The debt has declined by 48% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.